Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma

Zhang, Yawei; Wang, Rong; Holford, Theodore R.; Leaderer, Brian P.; Zahm, Shelia Hoar; Boyle, Peter; Zhu, Yong; Qin, Qin; Zheng, Tongzhang

doi:10.1007/s10552-006-0088-5

Cited by 5 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cocco et al, 2010). Apart from these, various studies Wang et al, 2007;Zhang et al, 2007;Villeneuve et al, 2009) reported an increased risk of NHL for those with a first degree relative diagnosed with a haematopoietic malignancy. This data indicates the importance of genetic predisposition for lymphoma risk (Skibola et al, 2007), and the interplay with environmental factors as the possible aetiological mechanism.…”

Section: Discussionmentioning

confidence: 99%

“…Strong risk factors for these lymphoid malignancies are genetic and acquired immunodeficiencies (Ekstrom Smedby et al , 2008), infectious agents (Hjalgrim & Engels, 2008) and several occupational exposures (Miligi et al , 2006; Cocco et al , 2010). Apart from these, various studies (Mensah et al , 2007; Wang et al , 2007; Zhang et al , 2007; Villeneuve et al , 2009) reported an increased risk of NHL for those with a first degree relative diagnosed with a haematopoietic malignancy. This data indicates the importance of genetic predisposition for lymphoma risk (Skibola et al , 2007), and the interplay with environmental factors as the possible aetiological mechanism.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Association of JAK‐STAT pathway related genes with lymphoma risk: results of a European case–control study (EpiLymph)

et al. 2011

View full text Add to dashboard Cite

Summary Previous studies have suggested an important role for the Janus kinase‐signal transducer and activator of transcription (JAK‐STAT) signalling pathway in tumour development. Therefore, we explored genetic variants in JAK‐STAT pathway associated genes with lymphoma risk. In samples of the EpiLymph case–control study we genotyped 1536 single nucleotide polymorphisms (SNPs) using GoldenGate BeadArray™ Technology (Illumina, San Diego, CA, USA). Here, we report the associations between selected SNPs and haplotypes of the JAK‐STAT pathway and risk of Hodgkin lymphoma (HL), B‐cell non‐Hodgkin lymphoma (B‐NHL) and most frequent B‐NHL subtypes. Among 210 relevant JAK‐STAT pathway‐related SNPs, polymorphisms in nine genes (BMF, IFNG, IL12A, SOCS1, STAT1, STAT3, STAT5A, STAT6, TP63) were significantly associated with lymphoma risk. At a study‐wise significance level, we obtained a risk reduction of 28% among carriers of the heterozygous genotype of the STAT3 variant (rs1053023) for B‐NHL. For six other variants within the STAT3 gene we observed an inverse association with different lymphoma subtypes. A reduced risk for HL was observed for the heterozygous genotype of the STAT6 SNP (rs324011). This is an explorative investigation to examine associations between JAK‐STAT signalling related genes and lymphoma risk. The results implicate a relevant role of certain pathway‐related genes in lymphomagenesis, but still need to be approved by independent studies.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Association of JAK‐STAT pathway related genes with lymphoma risk: results of a European case–control study (EpiLymph)

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Namely, if one twin develops cancer, the co-twin has an increased risk of developing cancer but not necessarily at the same site. Previous epidemiological studies of hematologic malignancies suggest that this is indeed the case; they report evidence of familial predisposition across both hematologic and non-hematologic malignancies [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. For instance, among women from Connecticut, lung cancer in first-degree relatives as well as breast and ovary cancer in siblings are associated with a significantly increased risk of NHL [ 12 ].…”

Section: Introductionmentioning

confidence: 90%

“…Previous epidemiological studies of hematologic malignancies suggest that this is indeed the case; they report evidence of familial predisposition across both hematologic and non-hematologic malignancies [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. For instance, among women from Connecticut, lung cancer in first-degree relatives as well as breast and ovary cancer in siblings are associated with a significantly increased risk of NHL [ 12 ]. Moreover, the results indicate a stronger association between siblings than parents [ 9 , 12 , 13 , 14 , 15 ].…”

Section: Introductionmentioning

confidence: 90%

Familial Risk and Heritability of Hematologic Malignancies in the Nordic Twin Study of Cancer

Clemmensen

Harris

Mengel‐From

et al. 2021

Cancers

View full text Add to dashboard Cite

We aimed to explore the genetic and environmental contributions to variation in the risk of hematologic malignancies and characterize familial dependence within and across hematologic malignancies. The study base included 316,397 individual twins from the Nordic Twin Study of Cancer with a median of 41 years of follow-up: 88,618 (28%) of the twins were monozygotic, and 3459 hematologic malignancies were reported. We estimated the cumulative incidence by age, familial risk, and genetic and environmental variance components of hematologic malignancies accounting for competing risk of death. The lifetime risk of any hematologic malignancy was 2.5% (95% CI 2.4–2.6%), as in the background population. This risk was elevated to 4.5% (95% CI 3.1–6.5%) conditional on hematologic malignancy in a dizygotic co-twin and was even greater at 7.6% (95% CI 4.8–11.8%) if a monozygotic co-twin had a hematologic malignancy. Heritability of the liability to develop any hematologic malignancy was 24% (95% CI 14–33%). This estimate decreased across age, from approximately 55% at age 40 to about 20–25% after age 55, when it seems to stabilize. In this largest ever studied twin cohort with the longest follow-up, we found evidence for familial risk of hematologic malignancies. The discovery of decreasing familial predisposition with increasing age underscores the importance of cancer surveillance in families with hematological malignancies.

show abstract

“…Several studies have investigated the relationships between familial hematopoietic cancer aggregation and hematopoietic cancer and suggest a 2‐fold increase in the risk of NHL21–24 and HL25 with a history of NHL in first‐degree relatives.…”

mentioning

confidence: 99%

Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: A French case–control study

Villeneuve

Orsi

Monnereau

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

Lymphoid neoplasms (LNs), including non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), lymphoproliferative syndrome (LPS) and multiple myeloma (MM), are among the most frequent cancers ( 17,000 new cases per year in France), after those related to smoking. LNs were investigated using the data from the ENGELA study. ENGELA is a multicenter hospitalbased case-control study that was carried out in France over the period September 2000-December 2004. In all, 822 cases (397 NHL, 149 LH, 168 SLP and 108 MM) and 752 controls were included and described 5,481 and 5,188 first-degree relatives, respectively. A positive association with a familial history of hematopoietic cancer was observed for LN (OR 5 1. were stronger for men. The associations were also stronger when the disease had been diagnosed before the relatives were aged 45 years. The results mainly support the involvement of genetic factors and suggest that at least some of those factors may be sex-linked. However, the slight overrepresentation of affected spouses among the cases might also support the responsibility of environmental factors. ' 2008 Wiley-Liss, Inc.Key words: epidemiology; lymphoid neoplasm; family; aetiology Lymphoid neoplasm (LN), including Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and lymphoproliferative syndromes (LPS), are among the most common cancers in France after smoking-related cancers. According to data from French registries, there were 17,000 new cases of LN in 2000 and almost 9,000 deaths. 1 In the last 2 decades , the yearly incidence rate for NHL has increased by more than 3% (3.8% for men and 3.5% for women), for reasons that have yet to be elucidated. 1 A few risk factors for LNs have been identified. They include congenital and acquired immunodeficiencies, 2-5 chromosomal instability syndromes, 6,7 Epstein-Barr virus (EBV) infection [8][9][10] for some Burkitt's 10,11 and HLs, Helicobacter pylori infection for gastric lymphoma 12,13 and some autoimmune disorders for nonHodgkin lymphoma. 14-17 Farming and exposure to pesticides [18][19][20] have also been consistently associated with LN.Several studies have investigated the relationships between familial hematopoietic cancer aggregation and hematopoietic cancer and suggest a 2-fold increase in the risk of NHL [21][22][23][24] and HL 25 with a history of NHL in first-degree relatives.This study analyzed the association between LN and familial history of cancer in the first-degree relatives of the subjects included in a large case-control study designed to investigate for environmental and genetic risk factors for LN. Material and methodsThe ENGELA study is a French multicenter hospital-based case-control study that was conducted in the main hospitals of Bordeaux, Brest, Caen, Nantes, Lille and Toulouse from September 2000 to December 2004 to investigate for environmental, infectious and genetics risk factors for LN. The LN types considered in the study were LPS, which included chronic lymphoid leukemia (CLL) and hairy cell leukemia (HCL),...

show abstract

Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma

Abstract: The risk associated with a family history of malignancies in first degree-relatives appears to vary by type of first-degree relatives.

Cited by 5 publications

References 43 publications

Association of JAK‐STAT pathway related genes with lymphoma risk: results of a European case–control study (EpiLymph)

Association of JAK‐STAT pathway related genes with lymphoma risk: results of a European case–control study (EpiLymph)

Familial Risk and Heritability of Hematologic Malignancies in the Nordic Twin Study of Cancer

Increased frequency of hematopoietic malignancies in relatives of patients with lymphoid neoplasms: A French case–control study

Contact Info

Product

Resources

About